Archived Newsletters
-
04.16.24 -- Why Are Cell-Therapy Outsourcers Unhappy? Investors Know
4/16/2024
04/16/24 Outsourced Pharma Newsletter
-
04.15.24 -- Leverage A Viral Vector Production Platform To Improve Efficiency
4/15/2024
04/15/24 Outsourced Pharma Newsletter
-
04.15.24 -- Getting To Know MAM, The New Quality Control Strategy On The Block
4/15/2024
04/15/24 Outsourced Pharma Newsletter
-
04.12.24 -- Impacts Of The Inflation Reduction Act (IRA)
4/12/2024
04/12/24 Outsourced Pharma Newsletter
-
04.11.24 -- From Ally To Adversary: BIO's Swift Rebuke Of WuXi
4/11/2024
04/11/24 Outsourced Pharma Newsletter
-
04.10.24 -- The Business of Biotech: Leaders in ADC Technologies
4/10/2024
04/10/24 Outsourced Pharma Newsletter
-
04.10.24 -- From Ally To Adversary: BIO's Swift Rebuke Of WuXi
4/10/2024
04/10/24 Outsourced Pharma Newsletter
-
04.09.24 -- From Ally To Adversary: BIO's Swift Rebuke Of WuXi
4/9/2024
04/09/24 Outsourced Pharma Newsletter
-
04.08.24 -- Shocking! Biotech Facilities Don't Maintain Themselves
4/8/2024
04/08/24 Outsourced Pharma Newsletter
- Best of March: Top 5 Insights in Outsourced Drug Development and Manufacturing 4/5/2024
This website uses cookies to ensure you get the best experience on our website. Learn more